Merck

Today, we announced the #FDA has approved two new treatments for certain patients with muscle-invasive #BladderCancer, expanding options for these patients. Learn more: go.merck.com/~app

Today, we announced an agreement with the AIDS Crisis Task Force to provide increased access to #HIV treatment for eligible people living with HIV through state AIDS Drug Assistance Programs (ADAPs). Learn more: go.merck.com/~8le

We’re proud to announce the #FDA approvals of two new immunotherapy-based treatment combinations for certain adults with advanced triple negative breast cancer (#TNBC). This milestone, in collaboration with @GileadSciences, is an important step forward in care for patients with this disease. Learn more: go.merck.com/~y66

Today, the European Commission approved a new treatment combination for certain patients with muscle-invasive #BladderCancer (MIBC). Together with Pfizer and Astellas Pharma, we’re proud to provide a treatment poised to address an important unmet need for these patients. Learn more: go.merck.com/~1li

Today, we shared positive topline results from a Phase 3 induction-only study in patients with moderately to severely active ulcerative colitis. These results reinforce our ongoing commitment to advancing immunology research. Learn more: go.merck.com/mv2

Today, we announced the FDA approval of an expanded indication that helps protect certain children and adolescents at increased risk for #pneumococcal disease. Learn more: go.merck.com/~us0

We're proud of today’s #FDA approval of new combination options for certain patients with earlier-stage #kidneycancer, who may face the possibility of their kidney cancer recurring after surgery. Learn more: go.merck.com/~p8f

In collaboration with @GileadSciences, we’re excited to announce positive topline Phase 3 results for our investigational once-weekly #HIV treatment for adults with virologically suppressed HIV: go.merck.com/~res

Click here for our latest oncology news: go.merck.com/~hn9

Today at #ASCO26, in collaboration with @moderna_tx, we're proud to present five-year follow-up results from a Phase 2b study evaluating our investigational individualized neoantigen therapy for #melanoma. Learn more: go.merck.com/~nws

@AdrianaJeffery Hi Adriana. We're sorry to hear your frustration. Please contact our National Service Center at dpoc.usa@merck.com or 1.800.672.6372 and they can do their best to address your concern.

@Merck what happened to the coupon for Janumet? Your website says you offer it but the link goes to a black 404 error page.

The U.S. FDA has granted Breakthrough Therapy designation for one of our investigational pipeline candidates for certain patients with KRAS G12C mutant non-small cell #lungcancer (#NSCLC). Learn more: go.merck.com/~bt8

@joshua_rogers15 Hi Joshua, your safety and the safety of our products is important to us. We’d appreciate the opportunity to learn more about your experience. Please contact the National Service Center at dpoc.usa@merck.com or call 1.800.672.6372.

@Merck Hey wait a min, I was given the wrong dose of then gardasil vaccine and that led to my injury. I still have to sue @nyulangone for medical malpractice. I wish I had known to start there but thank heavens for @forthepeople because their lawsuit has to change parties.

Today the CHMP issued a positive opinion of a new treatment combination for certain patients with muscle-invasive #BladderCancer (MIBC). Together with Pfizer and Astellas Pharma, we’re committed to advancing new options to address unmet needs. Learn more: go.merck.com/~4y2

Today, we announced the first positive Phase 3 results from our investigational TROP2-directed antibody-drug conjugate (ADC) in certain patients with advanced or recurrent endometrial cancer. This milestone represents the first results from our broad TroFuse clinical trial program and reflects our ongoing commitment to advancing research in women’s cancers. Learn more here: go.merck.com/~5pc

We’re presenting new data at #ASCO26 from our robust oncology portfolio and pipeline across earlier-stage and advanced tumor types. We’re focused on advancing research to fight cancer and evaluate new approaches to help prolong and protect lives. Learn more: go.merck.com/~k8y

Every day, our scientists tackle challenging problems like the scalable synthesis of complex molecules. In this latest publication in @ScienceMagazine, we share how we’re using #biocatalysis to manufacture orally available macrocyclic peptides. Learn more: go.merck.com/~4hh

Today, Merck completed the acquisition of Terns Pharmaceuticals, further strengthening our #oncology portfolio and reinforcing our focus on science‑driven innovation. Learn more: go.merck.com/~3wh

Join us today at 9 a.m. ET to learn more about our Q1 2026 #earnings: go.merck.com/~cn3 $MRK

Our Q1 2026 #earnings results are live. Check out our full $MRK financial summary and key highlights: go.merck.com/~e42